Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Cytokinetics (CYTK) Accumulated Depreciation & Amortization (2016 - 2025)

Cytokinetics (CYTK) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $47.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization changed N/A to $47.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $47.3 million for FY2025, N/A changed from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $47.3 million at Cytokinetics, up from $28.3 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $47.3 million in Q4 2025, with the low at $16.2 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 4 years is $27.2 million, with a median of $22.7 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization crashed 34.3% in 2021, then soared 65.84% in 2023.
  • Over 4 years, Accumulated Depreciation & Amortization stood at $16.2 million in 2021, then grew by 5.59% to $17.1 million in 2022, then surged by 65.84% to $28.3 million in 2023, then skyrocketed by 66.86% to $47.3 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $47.3 million, $28.3 million, and $17.1 million for Q4 2025, Q4 2023, and Q4 2022 respectively.